-+ 0.00%
-+ 0.00%
-+ 0.00%

Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

Benzinga·09/24/2026 11:43:06
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Buy rating and announces Price Target of $70.